News

Kite previously announced in March 2014 that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for KTE-C19 for the treatment of DLBCL. Further, Kite has

TRV130 is being developed as a first-line intravenous treatment for patients experiencing moderate-to-severe acute pain. The multicenter, randomized, double-blind, placebo- and active-controlled clinical trial is designed to evaluate

As part of the deal, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth about

Patient enrollment is scheduled to be completed by the end of January in this trial, which is being led by the Oxford Vaccine Group, part of the University

The open-label Phase II trial will enroll 54 patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL): 27 patients with diffuse large B-cell lymphoma and 27 with follicular lymphoma. Being carried

The company said that patients with advanced refractory solid tumors are being enrolled in the single-agent Phase Ia open-label dose-escalation trial. Currently, being conducted at four sites in

The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic

The collaboration brings together Amgen’s commitment to and capabilities in advancing new approaches in immuno-oncology and Kite’s industry-leading presence in CAR T cell therapy. Under the terms of

These high-risk patients typically do not respond well to standard therapies. These results were published in The Lancet Oncology. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and